The Discounted Cash Flow (DCF) valuation of Fulcrum Therapeutics Inc (FULC) is (13.72) USD. With the latest stock price at 5.63 USD, the upside of Fulcrum Therapeutics Inc based on DCF is -343.7%.
Based on the latest price of 5.63 USD and our DCF valuation, Fulcrum Therapeutics Inc (FULC) is a sell. selling FULC stocks now will result in a potential gain of 343.7%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 4.8% - 7.9% | 6.4% |
| Long-term Growth Rate | 3.0% - 4.6% | 3.8% |
| Fair Price | (140.20) - (7.28) | (13.72) |
| Upside | -2590.2% - -229.3% | -343.7% |